CRISPR’s Second Act: Editing the Epigenome to Tackle Cholesterol and Muscle Disorders

What if we could treat disease without ever cutting our DNA? While the first generation of CRISPR focused on genetic ‘scissors,’ a new wave of start-up firms is now targeting the epigenome. These companies are developing therapies that act like dimmers for gene expression, potentially offering safer treatments for conditions ranging from high cholesterol to rare muscular disorders.

As of June 26, 2026, these epigenetic markers are becoming the primary focus for biotech innovation. Unlike traditional gene editing, which physically alters the genetic sequence, epigenome editing leaves the DNA intact while changing how genes are read. This approach minimizes the risk of off-target mutations, making it a highly promising frontier for chronic and rare diseases alike. The industry is watching closely as these therapies move from the lab into clinical testing, marking a major milestone in precision medicine.